Stockscreener 앱 받기
3.49
11.15%
0.35
Adial Pharmaceuticals Inc 주식(ADIL)의 최신 뉴스
Adial Pharmaceuticals appoints David Rubenstein as chief scientist By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Appoints David Rubenstein as Chief Scientist - citybiz
Adial Pharmaceuticals appoints David Rubenstein as chief scientist By Investing.com - Investing.com India
Adial Pharmaceuticals names former Dermavant CSO as chief scientist - StreetInsider
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis - Yahoo! Finance Canada
The scientist who led development of an FDA-approved skin treatment will guide Adial's ulcerative colitis drug. - Stock Titan
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision - The Globe and Mail
Adial Pharmaceuticals adjourns votes pending Nasdaq listing approval, reconvenes Oct 15 - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
A new hire's right to buy 155,446 Adial shares vests over four years. - Stock Titan
Director at Adial Pharma (NASDAQ: ADIL) gets 25,666 stock options - Stock Titan
Adial Pharmaceuticals Removes Penalty Provisions in PIPE and Note Exchange to Restore Nasdaq Compliance - TradingView
Why Did Adial Pharmaceuticals (ADIL) Stand Out? - Kalkine Media
Why Did Adial Pharmaceuticals (ADIL) Stand Out? - kalkinemedia.com
Adial Pharmaceuticals Inc Warrant (ADILW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Adial Pharmaceuticals to replace CEO and CFO after 2026 annual meeting - scanx.trade
Adial PharmaceuticalsProposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling StockholdersSEC Filing - TradingView
Adial Pharmaceuticals files prospectus for resale of 25.1 million shares - scanx.trade
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
A new Adial employee gets a 307,814-share option at $5.76 - Stock Titan
Adial (ADIL) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Session Move - vinanet.vn
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks
Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Adial (ADIL) Watch: Ends Up by 5.42% at $6.22 in the Latest Reading; Price Context: $5.91 and $6.53 Define the Nearby Reference Levels in the Latest SessionSkew Index - vinanet.vn
Adial (ADIL) Financial Update: EPS Exceeds Its Estimate on the Day; Post-Report Move: Shares Move 9.22% Up at the CloseRevenue Breakdown Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn
Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals Releases Q2 2026 Financial Results - news.alphastreet.com
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Canada
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com UK
Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView
Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - GlobeNewswire
ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsWyckoff Spring - vinanet.vn
Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks
4.22%
자본화:
|
볼륨(24시간):